Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Travis T Wager

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
ACS Chemical Neuroscience|March 2, 2021
Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue TargetingNandini C Patel, Bo Feng, Xinjun Hou, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 18, 2011
Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioidsCamron D Bryant, Clarissa C Parker, Lili Zhou, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2019
In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain BarrierPatrick E Trapa, Matthew D Troutman, Thomas Y Lau, et al.
Scientific Reports|April 11, 2019
Author Correction: Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRsNoelia Ferruz, Stefan Doerr, Michelle A Vanase-Frawley, et al.
Scientific Reports|January 19, 2018
Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRsNoelia Ferruz, Stefan Doerr, Michelle A Vanase-Frawley, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
ACS Chemical Neuroscience|June 14, 2017
Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) InhibitorsTravis T Wager, Paul Galatsis, Ramalakshmi Y Chandrasekaran, et al.
ACS Chemical Neuroscience|October 10, 2014
Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behaviorTravis T Wager, Ramalakshmi Y Chandrasekaran, Jenifer Bradley, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
ACS Chemical Neuroscience|March 2, 2021
Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue TargetingNandini C Patel, Bo Feng, Xinjun Hou, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 18, 2011
Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioidsCamron D Bryant, Clarissa C Parker, Lili Zhou, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2019
In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain BarrierPatrick E Trapa, Matthew D Troutman, Thomas Y Lau, et al.
Scientific Reports|April 11, 2019
Author Correction: Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRsNoelia Ferruz, Stefan Doerr, Michelle A Vanase-Frawley, et al.
Scientific Reports|January 19, 2018
Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRsNoelia Ferruz, Stefan Doerr, Michelle A Vanase-Frawley, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
ACS Chemical Neuroscience|June 14, 2017
Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) InhibitorsTravis T Wager, Paul Galatsis, Ramalakshmi Y Chandrasekaran, et al.
ACS Chemical Neuroscience|October 10, 2014
Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behaviorTravis T Wager, Ramalakshmi Y Chandrasekaran, Jenifer Bradley, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Pageof 3